Thus overall, the data from this EPIC-Heidelberg nested case-control study indicate that together Se status and GPX1, SEPP1, TXNRD1, TXNRD2, and SELK genotype significantly alter risk of high-grade or advanced stage prostate cancer in a population with suboptimal Se intake. The gene discussed is TXNRD2; the disease is prostate cancer.